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A binary multiple logistical regression model was run where 28 day mortality was the dependent variable. All 141 plausible demographic and clinical data were first assessed for an association with 28 day mortality in a series of 142 univariable analyses. Variables with a p value <0.2 with 28 day mortality were then added to the multiple logistical 143 regression model as independent variables. The model was developed with backward selection. The majority of 144 variables, including our variables of interest, were dichotomous therefore precluding the need to test for linearity.
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We did not hypothesise any particular interactions in our model building process and our sample size was 146 insufficient to test for multiple interactions. Model building is described more systematically in the legend of 
Outcomes
Conversely, 28-day mortality was significantly higher in patients with positive PCR/ESI-MS assay in comparison to 199 those with negative PCR/ESI-MS result (62/147 (42%) versus 56/218 (26%), p=0.001 respectively). The odds ratio 200 for 28-day mortality when the microbial DNA was detected by PCR/ESI-MS assay was 2.1 (95% CI 1.4-3.3).
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In patients with negative blood culture results, a positive PCR/ESI-MS test result remained strongly associated with 202 increased rates of death (45/103 (44%) vs. 56/213 (26%), p=0.003, odds ratio for 28-day mortality 2.2 (1.3-3.6), 
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Univariable analyses demonstrated that increasing patient age (p<0.0001), a history of cancer (p=0.02), the presence 208 of immune suppression (p=0.04) and a higher SOFA score on admission (p<0.0001) were associated with an higher 209 risk of death at 28 days. None of: cardiovascular disease, respiratory disease, diabetes, chronic kidney disease, 210 cirrhosis or smoking history were associated with 28-day mortality. In a multivariable logistical regression model,
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when the significant covariates were added to the model the presence of a positive PCR/ESI-MS result remained 212 independently associated with 28-day mortality ( Table 3 and supplemental table 1). When the blood culture result 213 was also added to the model this was not independently associated with outcome but addition of the blood culture 214 result as a covariate further strengthened the association between the PCR/ESI-MS result and 28 day mortality. The principal finding of this analysis is that mortality was greater amongst patients referred to an ICU team for
factor in the failure to grow an organism using culture techniques. Alternatively, the presence of microbial DNA 279 may indicate the presence of active infection which a poorly sensitive test such as blood culture fails to identify. We 280 have previously reported that PCR/ESI-MS can readily identify fastidious and difficult to culture organisms [12] . It 281 is also plausible that a positive PCR/ESI-MS result is merely an epiphenomenon of more severe disease and perhaps 282 related to leakage of microbial contents from a porous gastrointestinal tract.
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We did not demonstrate an association between any individual microbial species and subsequent outcome but this 284 study is likely underpowered to detect any such an association. Furthermore, as the current PCR/ESI-MS technology 285 detects only KPC, vanA, vanB and mecA as antibiotic resistance genes and these were detected at a very low 286 frequency in our patients no definitive statement can be made regarding patient outcome in the presence of DNA 287 from highly resistant organisms. Although the presence of multi-drug resistant organisms is likely to have a 288 significant impact on determining patient outcome the relatively low incidence of culture positive sepsis in our 289 patients limited further analysis of this association.
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This analysis is specific to one particular methodology of microbial DNA detection -PCR/ESI-MS. A numerous 291 other technologies are available to detect microbial DNA. Two previous studies using other techniques did not 292 suggest that the detection of microbial DNA was associated with an higher mortality although they did report an 293 association between microbial DNA and a more severe acute illness [19, 20] . This has led many investigators to 294 question the relevance of microbial DNA in the bloodstream of a patient where viable microbes could not be 295 cultured [21] . That our study describes a mortality difference may be partly explained by the diagnostic spectrum of 296 the PCR/ESI-MS technology that is able to identify in excess of 800 microbes in a culture independent method in 297 comparison to other PCR technology that usually limits detection to approximately 25 common pathogens and 298 frequently requires enrichment via standard culture methodologies [19, 22, 23] .
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There are some limitations to the analyses presented here. During this study the PCR/ESI-MS result was not 300 available to the treating clinicians and therefore could not influence treatment whereas the blood culture results were 301 obtained as part of routine clinical care and results were available as normal. It is therefore plausible that patients 302 with negative blood cultures and positive PCR/ESI-MS results may have had their antibiotic treatment ceased 303 inappropriately early thereby affecting subsequent outcome. However, we found that the duration of antibiotic M A N U S C R I P T
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received adequate antibiotic treatment during the study period. Finally, although each institute obtained blood 309 cultures according to local protocols the lack of specific standardisation for this procedure could plausibly affect 310 microbial yield and thus study results.
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If replicated, these results could potentially alter management of the patients in the future. If the presence of 312 microbial DNA represents a sub optimally treated infected process then specific antibiotic regimes may be suggested 313 based on this test result. This approach would be greatly facilitated by the expanding the currently available panel of 314 antibiotic resistance genes detected by PCR/ESI-MS technology. As the field of sepsis immunotherapy and 315 personalised medicine rapidly expands PCR/ESI-MS may prove to have a role in identifying patients that would 316 benefit from specific antagonism of TLR9 pathways or even from adjunctive immune stimulation [24] [25] [26] . Further 317 mechanistic studies are required prior to suggesting more specific treatments. History of smoking 0.5 1.3 (0.7-2.7)
The C statistic for the whole model is 0.77. Abbreviations: OR, odds ratio; CI, confidence interval; SOFA, sequential organ failure assessment BC, blood culture. PCR/ESI-MS, Polymerase chain reaction followed by electrospray ionisation-mass spectrometry
